ICMJE DISCLOSURE FORM

Date	Eab 14st 2022		
			ential biomarkers of poor prognosis in triple-negative breast
cano		illioilliatic alialysis of pot	ential biolilarkers of poor prognosis in triple-negative breast
		TCR-22-662	
rela	ted to the content of your n	nanuscript. "Related" mean	relationships/activities/interests listed below that are is any relation with for-profit or not-for-profit third the manuscript. Disclosure represents a commitment
to tr	ansparency and does not no	ecessarily indicate a bias. I	f you are in doubt about whether to list a
rela	tionship/activity/interest, it i	s preferable that you do s	0.
	following questions apply to uscript only.	o the author [,] s relationship	os/activities/interests as they relate to the <u>current</u>
to th	•	nsion, you should declare	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive ne manuscript.
	em #1 below, report all sup time frame for disclosure is	·	I in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	
		needed)	
	-11	Time frame: Since the initia	l planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in		
	item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.		

Please place an "X" next to the following statement to indicate your agreement:

ICMJE DISCLOSURE FORM

Date	e:Feb. 14 st , 2022		
		nt Kamolphiwong	
Mar cand	nuscript Title: Integrated bio	informatic analysis of poto	ential biomarkers of poor prognosis in triple-negative breast
relate part to trelate	ted to the content of your miles whose interests may be ransparency and does not not it in the state of the s	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. I s preferable that you do s	relationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment of you are in doubt about whether to list a o.
to the	ne epidemiology of hyperten lication, even if that medica	nsion, you should declare a tion is not mentioned in the port for the work reported	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript. I in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	I planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	t 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

Consulting fees

X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
6	Payment for expert	X None	
	testimony		
	,		
7	Support for attending meetings and/or travel	XNone	
	J. Company		
8	Patents planned, issued or	XNone	
	pending		
	5	\ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	
9	Participation on a Data Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	XNone	
	-		
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.	

Please place an "X" next to the following statement to indicate your agreement:

		ICMJE DISCLOSURE F	ORM	
Date	e: Feb. 14 st , 2022			
You	r Name: Raphat	phorn Navakanitworakul		
			ential biomarkers of poor prognosis in triple-negative b	reast
cano				
Man	uscript number (if known):_	TCR-22-662		
relate part to tr	ted to the content of your n	nanuscript. "Related" mear affected by the content of ecessarily indicate a bias.	relationships/activities/interests listed below that are as any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment lf you are in doubt about whether to list a o.	
man	uscript only.		os/activities/interests as they relate to the <u>current</u> efined broadly. For example, if your manuscript pertains	
	ne epidemiology of hyperter lication, even if that medica		all relationships with manufacturers of antihypertensive he manuscript.	2
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other iten	ns,
		Name all entities with	Specifications/Comments	
		whom you have this relationship or indicate none (add rows as	(e.g., if payments were made to you or to your institution)	
		needed)		
		Time frame: Since the initia	l planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	XNone		
	processing charges, etc.)			
	No time limit for this item.			
		Time frame: pas	t 36 months	

Grants or contracts from

item #1 above).

Consulting fees

Royalties or licenses

3

4

any entity (if not indicated in

X__None

_X__None

_X__None

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	X None	
/	meetings and/or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	XNone	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.		

Please place an "X" next to the following statement to indicate your agreement:

ICMJE DISCLOSURE FORM

Dat	e:Feb. 14 st , 2022		
			tential biomarkers of poor prognosis in triple-negative breast
can		, .	
Mai	nuscript number (if known):_	TCR-22-662	<u></u>
rela part to t rela	ted to the content of your n ties whose interests may be ransparency and does not no tionship/activity/interest, it i	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. is preferable that you do s	
	rollowing questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t med	he epidemiology of hyperted dication, even if that medication.	nsion, you should declare tion is not mentioned in to the port for the work reporte	efined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript. d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initia	al planning of the work
1	All support for the present manuscript (e.g., funding,	XNone	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	st 36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated in		
	item #1 above).		
3	item #1 above). Royalties or licenses	X_None	

Consulting fees

X__None

_	Decima and a single	V. Nama	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and or travel		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
11	Stock of Stock options		
12	Descipt of agricument	V None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None.			

Please place an "X" next to the following statement to indicate your agreement: